4 completed. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 1 | Completed 1 |
Follow Eosinophilic Asthma: new trials by email Literature Review of Eosinophilic Asthma trials Research Report on Eosinophilic Asthma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma AD17002, Placebo - Eosinophilic Asthma | Phase 1 / Phase 2 | Completed | Advagene Biopharma Co. Ltd. | 40 | 2023-11-27 | 2025-09-10 |
| XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma XC8 100 mg, Placebo - Bronchial Asthma, Eosinophilic Asthma | Phase 2 | Completed | Chemlmmune Therapeutics LLC | 70 | 2020-12-16 | 2021-09-22 |
| Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma Dexpramipexole, Placebo - Eosinophilic Asthma, Asthma | Phase 2 | Completed | Knopp Biosciences | 534 | 2019-08-15 | 2023-04-13 |
| Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma Etokimab, Placebo - Eosinophilic Asthma | Phase 2 | Completed | AnaptysBio, Inc. | 25 | 2017-11-14 | 2023-08-16 |
Pulmonary Eosinophilia (4) · Asthma (2)
Eosinophilia (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Hypereosinophilic Syndrome (4) · Leukocyte Disorders (4) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Bronchial Diseases (2) · Hypersensitivity (2) · Hypersensitivity, Immediate (2) · Immune System Diseases (2) · Lung Diseases, Obstructive (2) · Respiratory Hypersensitivity (2)
Dexpramipexole (1) · heat-labile enterotoxin, E coli (1) · histamine glutarimide (1)
Advagene Biopharma Co. Ltd. (1) · AnaptysBio, Inc. (1) · Chemlmmune Therapeutics LLC (1) · Knopp Biosciences (1)
United States (2) · Russia (1) · Taiwan (1) · United Kingdom (1)
Bruce Randazzo, MD (1) · Han-Pin Kuo, MD. Ph.D. (1) · Yushen Hsu, Ph.D. (1)
2017 (1)